A GWAS of LC is being conducted in order to understand the role that genetic variation plays in LC risk among never-smoking women in Asia and to identify new genes or genomic regions that may be important in LC pathogenesis in never-smokers. International collaborations have been developed to facilitate accrual of blood or buccal cell DNA on a large set of LC cases. Through the collaborative efforts of FLCCA (Female Lung Cancer Consortium in Asia) that includes studies in Taiwan, Mainland China, South Korea, Japan, Hong Kong, and Singapore, we estimate that approximately 5,500 germline (blood or buccal cell) DNA samples of LC cases and a similar number of comparable controls will be genotyped at the NCI's Cancer Genomics Research (CGR) Laboratory or under contract at a facility in Beijing and subsequently available for GWAS analyses. Follow-up will include genotyping and sequence analyses of genomic regions associated with LC.
Note: Genotype data from this study is currently being prepared for dbGaP submission.